CoChat
Sign Up
Cited by 160Viral Infections and Immunology ResearchEvolution and Genetic DynamicsVirology and Viral Diseases

Evolution of the Sabin Strain of Type 3 Poliovirus in an Immunodeficient Patient during the Entire 637-Day Period of Virus Excretion

Open access
Martín, Javier, Dunn, Glynis, Hull, Robin, Patel, Varsha, Minor, Philip D.·2000·Journal of Virology
DOI 10.1128/jvi.74.7.3001-3010.2000PMC PMC111798
Open this paper in CoChat — free account

Abstract

A 20-year-old female hypogammaglobulinemic patient received monotypic Sabin 3 vaccine in 1962. The patient excreted type 3 poliovirus for a period of 637 days without developing any symptoms of poliomyelitis, after which excretion appeared to have ceased spontaneously. The evolution of Sabin 3 throughout the entire period of virus excretion was studied by characterization of seven sequential isolates from the patient. The isolates were analyzed in terms of their antigenic properties, virulence, sensitivity for growth at high temperatures, and differences in nucleotide sequence from the Sabin type 3 vaccine. The isolates followed a main lineage of evolution with a rate of nucleotide substitution that was very similar to that estimated for wild-type poliovirus during person-to-person transmission. There was a delay in the appearance of antigenic variants compared to sequential type 3 isolates from healthy vaccines, which could be one of the possible explanations for the long-term excretion of virus from the patient. The distribution of mutations in the isolates identified regions of the virus possibly involved in adaptation for growth in the human gut and virus persistence. None of the isolates showed a full reversion of the attenuated and temperature-sensitive phenotypes of Sabin 3. Information of this sort will help in the assessment of the risk of spread of virulent polioviruses from long-term excretors and in the design of therapies to stop long-term excretion. This will make an important contribution to the decision-making process on when to stop vaccination once wild poliovirus has been eradicated.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/jvi.74.7.3001-3010.2000

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The combined epidemiologic and virologic findings show that derivatives of the USOL-D-bac vaccine strain had spread extensively by person-to-person transmission for ~13 months.

    “however, the combined epidemiologic (101) and virologic (118) findings show that derivatives of the USOL-D-bac vaccine strain had spread extensively by person-to-person transmission for ∼ 13months.”

    From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [118]

  • Conclusive evidence for the vaccine origin of the Poland outbreak came from retrospective oligonucleotide fingerprinting and nucleotide sequencing studies of outbreak isolates.

    “conclusive evidence for the vaccine origin of the outbreak came from retrospective oligonucleotide fingerprinting (86) and nucleotide sequencing (118) studies of outbreak isolates.”

    From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [118]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 5

  1. [11]Fromtling J, Castañer J. Pleconaril (Win-63843) Drugs Future. 1997;22:40–44. [Google Scholar]
  2. [27]Magrath D I, Boulger L R, Hartley E G. 10th Symposium of the European Association against Poliomyelitis. Brussels, Belgium: European Association against Poliomyelitis; 1966. Strains of poliovirus from individuals fed Sabin vaccine studied by in vitro markers and the monkey neurovirulence test; pp. 334–345. [Google Scholar]
  3. [38]Sabin A B, Boulger L R. History of Sabin attenuated poliovirus oral live vaccines. J Biol Stand. 1973;1:115–118. [Google Scholar]
  4. [44]World Health Organization. Requirements for poliomyelitis vaccine (oral) WHO Tech Rep Ser. 1983;687:107–175. [Google Scholar]
  5. [45]World Health Organization. Draft report on the scientific basis for stopping immunisation against poliomyelitis meeting, March 23–25. Geneva, Switzerland: World Health Organization; 1998. [Google Scholar]

Cited by

Sorted by citations

Related

Authors
Martín, J., Dunn, G., Hull, R., Patel, V., & Minor, P. D.
Affiliations
  • <!--label omitted: 1-->Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom
  • National Institute for Biological Standards and Control (GB)
Venue
Journal of Virology
Publisher
American Society for Microbiology
Published
2000-04
Volume
74
Issue
7
Pages
3001-3010
ISSN
  • 0022-538X (ISSN-L)
  • 1098-5514
DOI
10.1128/jvi.74.7.3001-3010.2000
PMC
PMC111798
OpenAlex
W2146139689
Cited by
160
References
47
Citations by year
2025: 2 · 2024: 3 · 2023: 3 · 2021: 1 · 2020: 4 · 2019: 2 · 2018: 2 · 2017: 3 · 2016: 7 · 2015: 4 · 2014: 14 · 2013: 7 · 2012: 13
FWCI
4.21
Type
journal article
Language
en
Open access
Licence
journals.asm.org/non-commercial-tdm-license (tdm)
Locations
  • Journal of Virology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Viral Infections and Immunology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Evolution and Genetic Dynamics
  • Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
Keywords
hypogammaglobulinemia, antigenic variants, nucleotide substitution rates, temperature-sensitive phenotype, reversion, viral persistence, vaccine-derived poliovirus
MeSH terms
3C Viral Proteases, Adult, Agammaglobulinemia, Antigens, Viral, Capsid, Cysteine Endopeptidases, Female, Hot Temperature, Humans, Hydrolysis, Nervous System, Promoter Regions, Genetic, Protein Conformation, Viral Proteins, Virulence, Virus Shedding, Poliovirus, Evolution, Molecular, Amino Acid Substitution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review